

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number  
**WO 02/22886 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number: **PCT/US01/29096**

(22) International Filing Date:  
18 September 2001 (18.09.2001)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
60/233,339 18 September 2000 (18.09.2000) **US**

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US];** 614 Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: **ATTIE, Alan, D.;** 1906 Vilas Avenue, Madison, WI 53711 (US). **NADLER, Samuel, T.;** 909 South Brooks Apartment 7, Madison, WI 53715 (US).

(74) Agent: **SEAY, Nicholas, J.;** Quarles & Brady LLP, P.O. Box 2113, Madison, WI 53701-2113 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **EXPRESSION OF GENES IN DIABETES MELLITUS AND INSULIN RESISTANCE**

(57) Abstract: A gene expression pattern analysis has identified genes the expression patterns of which are different in adipose cells of individuals who have Type 2 Diabetes Mellitus from the cells of individuals who do not have the disease. This information provides a mechanism for the genetic diagnosis of the disease.

WO 02/22886 A2

EXPRESSION OF GENES IN DIABETES MELLITUS  
AND INSULIN RESISTANCE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from provisional patent application Serial. No. 60/233,339 filed Sept. 18, 2000.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH  
OR DEVELOPMENT

[0002] This invention was made with United States government support awarded by the following agency: NIH HL56593. The United States has certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] DNA microarrays are small dense arrays of DNA probes arranged on a substrate. The probes on the microarrays are arranged in cells, each of which contains only DNA probes derived from a single DNA sequence. When the DNA microarray is exposed to test mRNA of unknown or mixed sequence, the test nucleotides will hybridize or bind to the probes in one of more cells of the array. The test nucleotides will only bind to those probes the sequence of which is complementary to a DNA on the array. By intelligently constructing such DNA microarrays, it now is possible to construct microarrays which can be used to explore the expression patterns of human or animal genes during any number of physiological processes. For example, if a scientist had available a microarray including the complete set of the genes expressed by an organism, the scientist could then test against that array the mRNA produced in cells of various tissues of the organism during development. This would enable the scientist to determine which genes turn on and off when during the development of that tissue of the organism. Similar studies can be imagined to study disease susceptibility or progression.

[0004] Obesity is a strong risk factor for the development of Type 2 Diabetes Mellitus, a disease characterized by insulin resistance, relative insulin hyposecretion, and

hyperglycemia. In fact, over 80% of individuals with Type 2 Diabetes Mellitus are obese. However, only 10% of individuals who are obese are diabetic. It is still unclear what determines which obese, non-diabetic individuals will transition to diabetes.

[0005] In the course of transition from healthy to diabetic, it is common for obese individuals to become insulin resistant. The concept of insulin resistance is that the body becomes less sensitive, or even entirely insensitive, to insulin levels in the blood, and hence the metabolic activities triggered by insulin in normal individuals do not proceed or proceed at lower levels. As a result of that lowered metabolic response, the normal physiological feedback mechanisms cause the pancreas to increase insulin production to compensate for the insensitivity of the response to insulin. As the insulin response continues to decrease, insulin production continues to increase until, it is thought, the insulin producing cells are simply exhausted. Thus the onset of resistance to insulin may serve as a predictor of eventual diabetic disease in an individual.

[0006] The Obese mouse model represents a well-studied and accepted animal model for human obesity. These animals are homozygous for a gene, designated *ob*, which is a nonsense mutant form of the gene encoding leptin, a satiety factor secreted by adipocytes. The *ob* animals are markedly hyperphagic. However, despite extreme obesity, C57BL/6J (B6) *ob/ob* mice have only mild transient hyperglycemia. The *ob* mutation can be introgressed into the BTBR mouse strain to obtain severely diabetic mice. Together, these animals provide a functional animal model for the study of obesity present with or without diabetes.

#### BRIEF SUMMARY OF THE INVENTION

[0007] The present invention is summarized in that the first evaluation of the genetic basis for diabetic disease has now been made. The expression patterns of several genes have been characterized in change in individuals from healthy to diabetic. This makes possible the first genetic evaluations of individuals to determine susceptibility to type 2 diabetes.

[0008] The present invention also enables the design of genetic based tests for predicting and detecting the onset of insulin resistance based diabetes. This genetic analysis has revealed changes in gene regulation in adipocytes associated with the onset of this disease, this making it possible to assay for the gene regulation pattern in adipocytes in obese individuals to test for possible diabetic condition.

[0009] Other objects, advantages and features of the present invention will become apparent from the following specification.

#### BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[00010] None.

#### DETAILED DESCRIPTION OF THE INVENTION

[00011] While obesity is strongly correlated with Type 2 Diabetes, the role of obesity and genetics in the onset of this disease are not well understood. Here, for first time, the genes which have expression patterns diagnostic of the onset of diabetes are identified. This development makes possible the early diagnosis of the disease and early intervention so that the disease can be more successfully managed. In addition, also disclosed here are the genes the expression patterns of which change during the development of insulin resistance. Since the development of insulin resistance is a possible precursor to the development of diabetes, the identification of these gene expression patterns also provide diagnostic tools to identify or treat individuals at risk of developing diabetes.

[00012] This work made use of DNA microarrays to determine gene expression patterns in adipose tissue of obese individuals and in individuals having diabetes, using the mouse animal model. We used the DNA microarrays to identify changes in gene expression in both obesity and Type 2 Diabetes Mellitus. By using different strains of mice, we were able to identify those genes whose expression changed at onset of diabetes, independently of strain background. The identified genes are therefore most likely to be relevant in obesity and diabetes independent of other genetic background. Of the over 11,000 genes examined, over 200 genes showed consistent changes with obesity. Then because insulin resistance is a characteristic of the disease, we performed a similar study on mice that showed evidence of insulin resistance. In this study, we compared gene expression patterns in insulin resistant adipose tissue as compared to insulin sensitive adipose tissue. The insulin sensitivity was assessed by measuring the rate of glucose transport in response to insulin in freshly isolated adipocytes.

[00013] We were also able to identify a large number of genes whose level of gene expression in adipose tissue strongly correlated with the progression from normoglycemic obesity to obesity concomitant with diabetes. Of the genes that were evaluated by our

analysis, the expression of some changed with obesity alone, while the expression of others was identified as important in diabetes alone. A smaller subset of these genes, including the b-3 adrenergic receptor, demonstrated changes in expression in both diabetes and obesity.

[00014] This data shows that many of the changes in gene expression in diabetic adipocytes are a reversal of the pattern of gene expression which is characteristic of adipocyte differentiation. To facilitate that comparison, the genes in the tables below are organized in a manner similar to the patterns observed during the process of adipocyte differentiation. Cornelius et al., *Ann. Rev. Nutr.* 14, 99-129 (1994), organized the changes in gene expression observed in adipogenesis into five groups: hormone signaling and action, lipogenesis and lipolysis, cytoskeletal and extracellular, secreted, and proteins of unknown function. In this study, we observed changes in mRNA levels of 18 of those genes, distributed across four of the five classes. The expression levels of all but one of the genes changed in the opposite direction from the changes observed during adipocyte differentiation.

[00015] Tables 1, 2, and 3 attached to this specification summarize the results of this analysis. Table 1 lists the genes for which decrease levels of gene expression was found with increasing obesity in each mouse strain. The fold changes indicated in the tables are approximate, as the level of gene expression may have been outside the linear ranges of detection in one of the comparisons. Genes listed as [similar to] are ones which show sequence similarity with  $e < 5 \times 10^{-5}$ , Altsuch et al., *J. Mol Biol.* 215, 403-410 (1990). Table 2 shows the list of genes the expression of which increase with increased obesity. Table 3 lists the changes in gene expression that correlated with the development of hyperglycemia. The R-values in Table 3 are calculated using the rank order of the five sets of animals with increasing hyperglycemia. Here fold changes represented by [n/a] means that the mRNA level increased from, or decreased to, an expression level outside the linear range of detection.

[00016] In the tables, the genes are organized into groups, similar to the groupings of gene expression patterns as previously identified during the differentiation of adipocytes. In Table 1, there are groups of genes associated with hormones and signal transduction, mitochondrial function, lipid metabolism, transcription factor, secreted proteins, and others. In Table 2, the genes are grouped as cytoskeletal and ECM, lysosomal, immune/complement genes, cell proliferation genes, adipose-specific genes, membrane proteins and others. In Table 3, the gene groupings are signal transduction, secreted proteins, protein synthesis and

processing, cytoskeletal and ECM, transcription factors, others and metabolism genes.

[00017] One strategy to design a diagnostic test for the initiation of progression to insulin resistance or diabetes would be to assay for changes in the level of expression of any of the genes in Tables 1, 2 or 3. Any of these genes could be combined with assays for the level of expression of any others to test for this progression. An assay testing the expression level of a larger number of genes would add to the confidence in the result, but testing all of the genes on the tables would not be necessary or appropriate.

[00018] In one useful strategy for the construction of a panel or array to test for progression to insulin insensitivity or to diabetes, one would select a representative gene from each of four different gene groupings as listed either or both of Table 1 or 2. The assay would then test for the associated increase or decrease in gene activity associated with the progression. For example, an assay might look at the expression level of one lipid metabolism gene from Table 1, one transcription factor gene from Table 1, one signal transduction gene from Table 2, and one secreted protein from Table 2. Of course, one would look for decreases in gene expression in the gene selected from Table 1 and increases in gene expression for the genes selected from Table 2. The selection of genes from four different groupings adds to the reliability of the assay by demonstrating that differing cellular functions are demonstrating the effect. For an assay of increased stringency, genes from six or either different gene groupings could be used.

[00019] One particularly significant gene which is a candidate for inclusion in any such assay is SREBP (Table 1). This gene encodes a protein transcription factor, which means that the expression of this gene triggers activation of a series of additional genes in the adipose cell. Thus changes in the level of expression of this gene are magnified in effect. An assay for the level of expression of this gene may be the most significant of the genes listed in the tables, and a sensitivity to any decrease in the level of expression of this gene is an observation that should be accorded significance. The data indicates that the level of expression of SREBP is a good predictor of susceptibility to diabetic disease.

[00020] In all three tables, the genes from the mouse insulin model are identified by reference to GenBank accession numbers. In each table as well, the homologous human gene is also listed by reference to GenBank accession numbers. The human gene are exemplary, and other homologs may be used as well. Obviously, in an assay intended to diagnose human disease, the human genes should be used. All the respective gene sequences can be retrieved

in their entirety from the GenBank depository on-line with these accession numbers, as is well known to those of skill in this art.

**[00021]** Changes in gene expression in adipose tissue alone might or might not be sufficient to cause diabetes. Alterations in muscle, liver and pancreatic b-cells are probably also required. However, recent studies in mice that lack white adipose tissue show that adipocytes play an important role in the development of diabetes. For example, transgenic mice lacking adipose tissue due to disruption of transcriptional regulation by C/EBPs and Jun, develop hyperglycemia and hyperinsulinemia, two hallmarks of type 2 diabetes. Similarly, adipocyte-specific overexpression of a constitutively active form of SREBP leads to dramatic loss of white adipose tissue and subsequent development of diabetes in mice. It is currently believed that a change in lipogenic capability in adipose tissues is certainly indicative of a change to insulin resistance and may be a causative agent for the development of diabetic disease.

**[00022]** The changes in gene expression that we observed are provocative in that the onset of diabetes in our model system correlated with alterations in the expression of many mRNAs coding for signal transduction proteins that have been previously implicated in diabetes. For example, Fyn mRNA levels increased with hyperglycemia. Fyn has recently been implicated in the compartmentalization of insulin signaling through its interaction with c-Cbl. Similarly, we observed an increase in mRNA for Flk-2, a tyrosine kinase that promotes hematopoiesis through interactions with Grb2 and Shc, two important mediators of insulin signaling.

**[00023]** The expression of many transcription factors correlated with diabetes. Expression of BF-2 and int-1 both increased with diabetes. BF-2 has been described in the context of neuronal development and belongs to the same family as HNF3, an important adipogenic transcription factor. Int-1 is a proto-oncogene involved in the proliferation of mammary tumors. A decrease in mRNA levels was observed for the transcription factors Dishevelled-3 (Dvl-3), Dlx5, and Pale Ear (ep). No association between hyperglycemia and Dishevelled-2 or Dlx5 has been previously reported. The potential role of Pale Ear in diabetes progression is intriguing. Mutations in the orthologous human gene cause Hermansky-Pudlak syndrome in humans, a rare disorder associated with impaired vesicular transport, a critical process in insulin-stimulated glucose uptake.

**[00024]** The mRNA levels of another protein implicated in vesicular transport, tctex-1,

decreased with diabetes. Tctex-1 comprises one of the three light chains in cytoplasmic dynein. It plays an important role in many aspects of membrane and vesicular transport. Impaired ability of cells to translocate glucose transporter-containing vesicles to the plasma membrane in response to insulin would result in insulin resistance, an important contributor to the development of Type 2 Diabetes Mellitus.

[00025] The work described here uses an 11,000 gene murine microarray. Since the total number of genes in the murine genome is currently unknown, but is probably in the range of 50,000 to 150,000 genes, these 11,000 genes represent a sample of perhaps 5-20% of the genome, although they probably contain a higher percentage of genes expressed in adipose tissues. The microarray, commercially available from Affymetrix, Inc., is known as the murine 11k array.

[00026] The data presented in this specification can be used both for the study of the onset of diabetic disease as well as providing a tool for developing diagnostic tests for the disease. The genes listed in Table 3 represent the changes to the molecular genetics of the adipose cell which are responsible for the evolution of the cells to a state of diabetic disease. By continuing to correlate this information to the actual occurrence of disease, it will become possible to determine which among the expression patterns of these genes are actually definitive for the onset of diabetic disease. Then that information can be used as a definitive test for the disease. In addition, one can readily envision a diagnostic test, consisting for example of a microarray containing probes for each of the genes in the tables, by which the expression patterns of those genes can be measured in an individual to determine whether that individual has diabetes or has the genetic predisposition to develop diabetes.

[00027] It is also envisioned that the information presented here will be valuable to design techniques for intervention in the progression of diabetes disease. Many genes are shown here to be either up-regulated or down-regulated in adipose cells as an individual first becomes insulin resistant and then diabetic. Given the techniques of gene therapy now available to use this information to design intervention strategies to counteract that gene expression pattern. The idea is that one would up-regulate genes which would otherwise be in the process of down-regulation and down-regulate genes which were over-expressing. It is possible to up-regulate genes in mammals by adding additional copies of the genes to cells by gene therapy or by triggering up-regulation of genes by introducing known inducing substances into the individual. For down-regulation, one could introduce an anti-sense



genetic construction into the individual or one could use a drug which is known to have a down-regulating effect on the targeted gene. This data thus provides an intervention mechanism through which it is possible to prevent the progression into diabetic disease.

[00028] While the data presented here was gathered in a murine animal model, the data should be largely useful as well in humans, using the human homologous genes. Of course, for a human test the genes which would be assayed would be the human analogous of the listed murine genes, but the availability of the entire human genomic sequence makes this analysis both possible and practical.

### EXAMPLES

[00029] **Animals.** BTBR, B6 and B6-*ob*/+ mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred at the University of Wisconsin Animal Care Facility. Mice were housed on a 12 hour light-dark cycle and had *ad libitum* access to regular chow (Purina #5008) and water. All protocols were approved by the University of Wisconsin - Madison Institutional Animal Care and Use Committee.

[00030] **Sample Preparation.** Epididymal fat pads were isolated from 14-week old mice after a 4-hour fast, and snap frozen in liquid nitrogen. Total RNA was isolated using TriReagent (Molecular Research Center, Inc., Cincinnati, OH). cDNA was prepared from equal amounts of total RNA pooled from at least 4 animals using Superscript Choice System (GibcoBRL, Grand Island, NY) with a primer containing oligo-(dT) and T7 RNA polymerase promoter sequences. Biotinylated cRNA was synthesized from purified cDNA using the Bioarray High Yield RNA Transcript Labeling Kit (Enzo, Farmingdale, NY). cRNA was purified using RNeasy columns (Qiagen, Valencia, CA), and quantified by

[00031] **Microarrays.** Samples for DNA microarray hybridization were prepared as described by Lockhart et al., *Nat Biotech.* 14, 1675-1680 (1996). Hybridization to Murine 11K arrays was performed for 16 hours at 45°C. Microarrays were washed according to Affymetrix protocols and immediately scanned on a Hewlett-Packard GeneArray Scanner

[00032] **Data analysis.** All data sets were normalized to total fluorescence, which represents the total amount of cRNA hybridized to a microarray. The threshold for determining the significance of a change in the level of gene expression was made using an algorithm that requires both a significant absolute and fold change. Identification of genes associated with obesity was determined by selecting only those genes that significantly

increased or decreased in every comparison.

[00033] Gene expression levels that changed with diabetes were identified by linear regression performed on five groups of animals with increasing hyperglycemia. The correlation between expression levels and rank order of the five groups of animals was determined. This method was preferred to several clustering methods as it focuses specifically on linear trends. Similar genes were observed to change when regressions were performed with average fasting glucose levels of the group of animals instead of the rank order. Genes that correlated with  $R > 0.95$  or  $R < -0.95$  and had at least 3 absolute expression levels within the limits of detection were selected.

[00034] The strains of lean mice, C57BL/6J, BTBR, and BTBR x B6 F1 (BtB6 F<sub>1</sub>), all have normal fasting glucose levels. The *ob* allele causes extreme obesity, but only mild, transient hyperglycemia in the B6 background, (fasting plasma glucose  $210 \pm 30.7$  mg/dl) as separately described (Stoehr, et al., submitted). In contrast, introgression of *ob* into BTBR animals caused both obesity and severe diabetes with fasting plasma glucose levels of  $549 \pm 24.5$  mg/dl. Obese animals derived from a cross between BTBR and B6 (F<sub>2</sub> *ob/ob*) showed a large range of fasting glucose levels (150-750 mg/dl). Therefore, this F<sub>2</sub> population was a means of obtaining obese mice exhibiting different degrees of diabetes.

[00035] **Gene Expression in Lean and Obese Mice.** The gene expression profile of adipose tissue from lean and obese animals in several mouse strains were compared. We assessed the mRNA levels of > 11,000 genes. About 10% of the assessed genes showed significant changes in gene expression in either direction. We then compared the gene expression change in each independent comparison and selected only those genes whose expression significantly increased or decreased in every comparison. The ability to detect important alterations in mRNA levels was increased not only by having three independent comparisons, but also through the elimination of strain background as a variable - the genes identified changed regardless of strain. This led to the identification of 136 genes (1.2%) whose expression consistently increased across every comparison and 78 genes (0.7%) with consistently decreased expression levels. These numbers were significantly greater than the number expected by random chance, 3 and 2 genes, respectively ( $p < 0.001$ , chi-square). We reconfirmed the change in gene expression in 16 genes by semi-quantitative RT-PCR and/or northern blots and observed qualitative agreement between the methods for all 16 genes (data not shown).

[00036] We were surprised to note that many of the changes in gene expression are the opposite of those previously shown to characterize adipocyte differentiation (Table 1). Several mRNAs that encode proteins involved in lipid metabolism were decreased. These included: ATP-citrate lyase, glycerol 3-P dehydrogenase, stearyl CoA desaturase and fatty acid binding protein. Adipocyte-specific mRNAs, such as spot14 and adipsin, decreased 4.3- and 8.6-fold respectively. However, leptin mRNA increased, consistent with previous reports in *ob/ob* mice. Furthermore, genes involved in energy metabolism also showed marked decreases, including aldolase, lactate dehydrogenase and pyruvate carboxylase. Other markers of adipocyte differentiation not directly involved in energy metabolism also showed decreases. For example, the expression of  $\beta$ -3 adrenergic receptor, angiotensinogen, and apolipoprotein E all increase during adipogenesis but showed large decreases in the comparisons of adipose tissue from lean and obese mice.

[00037] Another surprising result was the number of genes encoding mitochondrial enzymes whose expression decreased with obesity. Several proteins involved in the electron transport chain, such as cytochrome c1 and cytochrome c oxidase, decreased. The mitochondrial enoyl-CoA hydratase and aldehyde dehydrogenase 2 also showed 2.2- and 2.8-fold decreases, respectively. In contrast, uncoupling protein 2 (UCP2) increased 4-fold in adipose tissue from obese animals.

[00038] Large increases in gene expression were observed in genes coding for cytoskeletal and extracellular matrix proteins (Table 2). Expression of type I collagen decreases during adipocyte differentiation but we observed a 2.1-fold increase in the expression of procollagen I. We observed increases in profilin, talin, and actin-binding protein mRNAs consistent with the need to remodel fat pads as adiposity increased. Changes in genes encoding extracellular matrix proteins included increases in the expression levels of cofilin, galactose-binding lectin and the proteoglycan biglycan. Cathepsins are lysosomal proteases also implicated in tissue remodeling. Increases in expression of cathepsins B and D as well as cathepsin K, S, and Z precursors were observed with obesity.

[00039] The expression level of certain nuclear proteins and transcription factors was also altered. The gene encoding the Myc basic motif homolog-1 showed a 3.0-fold increase in obese animals. Of particular note, the sterol responsive element binding protein ADD1/SREBP demonstrated a 2.7-fold decrease in expression. SREBP positively regulates many genes coding for lipogenic enzymes and its down-regulation is consistent with the

decrease in expression of the lipogenic enzymes mentioned above.

**[00040] Gene Expression in Obese and Obese-Diabetic Mice.** We determined which genes increased or decreased with hyperglycemia across five sets of mice: B6 *ob/ob* mice, three sets of F<sub>2</sub> *ob/ob* mice with increasing hyperglycemia (mean fasting glucoses of 299, 337, and 410 mg/dl), and BTBR *ob/ob* mice. By generating an F<sub>2</sub> *ob/ob* population from the parental strains, we created mice with intermediate levels of hyperglycemia ranging from very mild to severe. This allowed us to assess which genes demonstrate a dose-dependent change in gene expression with increasing hyperglycemia. The degree of correlation between the severity of diabetes and gene expression levels was evaluated by linear regression. In white adipose tissue, there were 34 genes (0.3%) whose expression positively correlated ( $r > 0.95$ ) and 58 genes (0.5%) whose expression negatively correlated with diabetes ( $r < -0.95$ ). As before, we reconfirmed the change in expression for selected genes. The fold change was calculated from the expression levels of the groups with the lowest and highest blood glucose. Many genes that code for signal transduction proteins had expression levels that correlated with the development of diabetes. Genes similar to both Raf and Ras increased with diabetes, as did Fyn. Many signal transduction molecules use SH2 and SH3 domains, and two such proteins, SH3P3 and CISH, decreased with diabetes.

**[00041]** Our analysis also identified several genes encoding proteins involved in protein phosphorylation and dephosphorylation, important mediators of many signaling pathways, including those activated by insulin. In particular, PTPK1, a non-receptor protein tyrosine phosphatase, decreased to undetectable levels as hyperglycemia increased. The expression of Flk-2, a class III receptor tyrosine kinase, increased from undetectable levels with the onset of diabetes. Conversely, CAM-like protein kinase and pim-1 protein kinase decreased significantly with hyperglycemia whereas a phosphatase inhibitor-2-like protein increased with elevated plasma glucose. Expression of vav-T, an SH3 domain containing G-protein exchange factor, decreased 3.3-fold. We also observed that many transcription factor mRNA levels changed with worsening diabetes. BF-2, a winged helix transcription factor, and int-1 increased 2- and 4-fold respectively. Other transcription factors, such as Dlx5, *Disheveled* (Dvl3), and *Pale Ear* (ep) decreased with diabetes.

**[00042]** The expression of several genes involved in energy metabolism changed with hyperglycemia. Klbp, a lipid binding protein, increased 7.3-fold while long-chain acyl-CoA dehydrogenase decreased 1.6-fold. AKR1, an aldo-ketoreductase, and fructose-1,6 bis-

phosphatase both increased. Interestingly, the b-3 adrenergic receptor decreased 90% in obesity but was positively correlated with increasing plasma glucose. Genetic variations in the the b-3 adrenergic receptor have previously been associated with Type 2 Diabetes Mellitus.

**Table 1. Genes with decreased expression with obesity in each mouse strain.**

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
<i>Hormones and signal transduction</i>			
x72862	$\beta$ -3-adrenergic receptor	-10.5	XM_049417
aa500440	GTP-binding protein ( $G_{\alpha i-1}$ )	-2.3	AF205588
aa529056	Guanine nucleotide binding protein 11	-1.6	XM_004660
u02602	Thyroid stimulating hormone receptor	-1.5	XM_007404
X61431	Diazepam-binding inhibitor	-2	M14200
AF009246	Ras-related protein (DEXRAS1)	-2.9	NM_016084
<i>Mitochondrial</i>			
aa245912	Similar to succinate dehydrogenase	-2	NM_003000
aa466050	Similar to cytochrome <i>c</i> 1	-1.8	BC001006
aa667872	Similar to ubiquinol-cytochrome <i>c</i> Reductase core protein 2	-3.4	NM_003366
aa733351	Similar to ATP synthase E chain	-2.1	NM_007100
W42043	Branched-chain amino acid aminotransferase	-2.8	U68418
W41817	Cytochrome <i>c</i> oxidase, subunit VIIIa	-2.7	XM_006132
U07235	Aldehyde dehydrogenase (ALDH2)	-3	XM_007012
D16215	Flavin-containing monooxygenase	-2.8	XM_001726
Aa270965	Mitochondrial enoyl-CoA hydratase	-2.8	N/a
M60798	SOD-1	-2.2	XM_047885
<i>Lipid metabolism</i>			
D29016	Squalene synthase	-1.8	L06105
Aa271471	ATP citrate-lyase mRNA	-2.9	XM_036462
D50430	Glycerol-3-phosphate dehydrogenase	-2.5	XM_050502
X51905	Lactate dehydrogenase-B	-3.3	XM_050074
M21285	Stearoyl-CoA desaturase	-2.5	XM_030446
L09192	Pyruvate carboxylase	-2.1	NM_022172
Y00516	Aldolase A	-2.5	BC010660
AA080172	Phosphoenolpyruvate carboxykinase	-5.3	XM_009672

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
W29562	3T3-L1 lipid binding protein	-2.3	XM_005096
X95279	Spot14	-4.6	Y08409
aa197973	Similar to biotin carrier protein of methylmalonyl-CoA carboxyl- transferase	-2.4	XM_037615
<i>Transcription factor</i>			
AA068578	add1/SREBP	-2.7	U00968
<i>Secreted proteins</i>			
AA106347	Angiotensinogen precursor	-8.1	BC011231
W36455	Adipsin	-8.3	AJ313463
D00466	Apolipoprotein E gene	-2.4	M10065
m60579	Coplement componenet C2	-3.2	XM_004193
<i>Others</i>			
U63146	Retinol-binding protein (RBP)	-2.5	XM_005907 AF119868 NM_006744 X00129
AA049662	Retinol-binding protein (RBP)	-2.2	XM_005907 AF119868 NM_006744 X00129
W14367	Retinol-binding protein (RBP4)	-1.8	XM_005907 AF119868 NM_006744 X00129
AA154594	Similar to branching enzyme	-2.6	XM_011011
W85270	Inorganic pyrophosphatase	-2	XM_045578
W13498	Glycogen phosphorylase	-2.5	N/A
AF012431	D-dopachrome tautomerase (Ddt)	-1.9	AF058293
L31783	Uridine kinase	-2.7	XM_033387
U38940	Asparagine synthetase	-4	XM_044503
X51703	Ubiquitin	-2.7	XM_037118
aa688469	Osteogenesis imperfecta (oim)	-3.3	XM_042194
ab004048	Neuronatin	-2.8	XM_009686
m30844	B2 protein	-11.2	AF144686
U19596	Cdk4 and Cdk6 inhibitor p18	-2.7	XM_001304
X14061	$\beta$ -globin complex	-2.6	N/A
W82026	Scr3, ssRNA BP	-2.1	D28483
W83919	Elongation factor Tu	-2.3	XM_017048
M73483	Glutathione S-transferase	-5.8	XM_037077
M96827	Ob/ob haptoglobin	-2.1	NM_005143
AA059700	$\beta$ -2 microglobulin (B2m)	-3.2	XM_032402
ET61037	TI-225	-2.5	N/A

**Table 2. Genes with increased expression with obesity.**

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
<i>Cytoskeleton and ECM</i>			
X54511	Myc basic motif homologue-1	15	BC000728
d00472	Cofilin	1.7	XM_053779
m86736	Acrogranin	2.7	XM_045991
u08020	FVB/N collagen pro- $\alpha$ -1	2.1	XM_012651
u27340	Sulfated glycoprotein (Sgp 1)	3.1	XM_045137
x56123	Talin	7.7	XM_005392
W10936	L-34 galactoside-binding lectin	4.5	NM_002306
AA003323	Similar to filamin A	4.5	NM_001456
X99347	LPS-binding protein	1.9	XM_012965
X14425	Profilin	2.1	XM_028379
X75285	Fibulin-2.	2.2	XM_051629
L20276	Biglycan (Bgn)	2.1	BC004244
D13664	Osteoblast specific factor 2 (OSF-2)	3.1	NM_006475
<i>Lysosomal</i>			
aa255186	Similar to cathepsin S precursor	5.6	XM_041904
X94444	Preprocathepsin K.	4.5	XM_041899
AA106931	$\gamma$ -IFN inducible lysosomal thiol reductase (GILT)	6	XM-038147
M65270	Cathepsin B	3.5	N/A
AA116604	Cathepsin Z precursor (Ctsz)	3.9	XM_030701
AA107895	Cathepsin D	2.1	XM_006121
AA146437	Cathepsin S precursor	7.7	XM_041904
ab009287	Macrosialin	6.6	AC007421
AA000961	Preprolegumain	3.9	D55696
AA117064	Vacuolar adenosine triphosphatase	1.9	XM_005227
<i>Immune/ complement genes</i>			
aa711625	Similar IFN- $\alpha$ induced protein	2.8	XM_016486
ET62967	Complement C1q precursor	1.4	N/A
m22531	Complement C1q $\beta$ chain	2.6	XM_010666
J05020	High affinity IgE receptor	2.5	XM_042451
m14215	Fc $\gamma$ receptor	4.8	X17652
W41745	Fc receptor (Fcer1 $\gamma$ )	8.1	XM_042451
L39357	Migration inhibitory factor (Mif)	1.6	L19686
u19482	C10-like chemokine	3.3	N/A
Z11974	Macrophage mannose receptor	3.7	XM_005830
X67469	AM2 receptor	1.7	NM_002332
L20315	MPS1	5.4	L20314
X91144	P-selectin glycoprotein ligand	2.8	XM_006867
Z16078	CD53 gene exon 7	2.2	L11670

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
<i>Cytoskeleton and ECM</i>			
W11011	Nedd8	1.4	XM_017573
W08269	Pigment epithelium-derived factor	2.3	AF400442
AA097711	Tropomyosin (TM-4)	2.2	BC002827
U72680	Ion channel homolog RIC	3	XM_015774
AA096813	Cysteine proteinase	2.2	AC009123
M73741	$\alpha$ -B2-crystallin gene	2.8	M28638
W15873	Similar to Tctex1	1.5	D50663
<i>Cell proliferation</i>			
U44426	D52 (mD52)	5.2	XM_005272
X06368	c-fms proto-oncogene	2.5	XM_003789
J05261	Mouse protective protein (Mo54)	2.6	XM_009489
AA050703	Defender against cell death 1	1.7	XM-033470
<i>Adipose- specific genes</i>			
M93275	ADRP	4.2	XM-048266
U18812	Leptin	3	XM_045426
<i>Membrane proteins</i>			
W64897	Phosphatidylinositol transfer protein	1.8	NM_006224
u37226	Phospholipid transfer protein	3.4	XM_009490
AA031158	Brain acid-soluble protein 1	4.5	NM_0006317
AA108956	Similar to human membrane protein	1.8	L09260
AF026124	Schwannoma-associated protein	3.9	XM_047409
AA108330	Astrocytic phosphoprotein	1.9	XM_001279
<i>Others</i>			
u69135	UCP2	4.3	BC011737
u29539	Retinoic acid-inducible E3 protein	3.4	U30498
U59807	Cystatin B (Stfb)	4.4	AC079869
K02236	Metallothionein II (MT-II)	2.6	J00271
M38337	Milk fat globule membrane protein E8	3.1	XM_031292
M73706	Ferritin large subunit	1.9	XM_050469
W75072	Creatine kinase B	3.4	N/A
W83564	5-lipoxygenase-activating protein	3.4	XM_015396
AA106783	Poly A binding protein	1.8	XM_042055
x84797	Similar to human hematopoietic specific protein 1	4	NM_005335
X61970	Growth factor-inducible immediate early gene (3CH134)	2.6	XM_003720



**Table 3. Genes correlated with the development of hyperglycemia.**

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>r value</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
<i>Signal transduction</i>				
M34397	IL-3 receptor-like protein	-0.955	-3.5	XM_009960
aa097386	Similar to CAM-like protein kinase	-0.982	n/a	XM_002911
U58889	SH3-containing protein (SH3P3)	-0.970	n/a	XM_005175
u35124	Nonreceptor tyrosine phosphatase	-0.968	n/a	XM_002447
d31943	Cytokine inducible SH2-containing protein	-0.971	-2.2	XM_002835
u60528	Guanylin precursor gene	0.963	n/a	N/A
aa217487	Similar to mouse pim-1 protein kinase	-0.972	n/a	M16750
m64689	flk-2	0.972	n/a	XM_039994
C79373	Similar to phosphatase inhibitor-2	0.952	1.5	XM_049288
aa105135	Similar to P53-binding protein	-0.982	-2.4	XM_032359
aa467011	Similar to LMW G-protein	0.955	n/a	XM_031430
d83266	vav-T	-0.958	n/a	XM_044621
W91283	Similar to human ras-like protein	0.989	1.6	M31468
C81377	Similar to rat activated c-raf oncogene	0.960	n/a	XM_051580
u70324	Fyn(T)	0.965	n/a	XM_040354
X72862	$\beta$ -3-adrenergic receptor	0.951	n/a	XM_049417
L01695	Calmodulin-dependent phosphodiesterase	-0.960	-1.2	XM_006812
x04648	IgG1/IgG2 $\beta$ Fc receptor (FcR)	-0.961	-3.3	X17652
<i>Secreted proteins</i>				
M33960	Plasminogen activator inhibitor (PAI-1)	0.962	2.2	XM_051248
D38580	VNSP 1 (vomeronasal secretory protein I)	-0.962	n/a	XM_009475
<i>Protein synthesis and processing</i>				
aa036204	Similar to human 40S ribosomal protein S24	0.971	1.7	XM_051716
D12907	47-kDa heat shock protein (HSP47)	-0.966	-1.6	NM_004353
L25913	Chaperonin	0.999	1.5	AF026291
C77806	Similar to rat carboxypeptidase B gene	-0.960	n/a	AF144685
aa270493	Similar to deoxyhypusine synthase	-0.959	-2.4	XM_032647
aa611449	Similar to <i>Homo sapiens</i> HSPC183	-0.962	-2.6	AF151017
AA105758	MDj10	-0.974	-2.2	XM_032485

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>r value</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
<i>Cytoskeletal and ECM</i>				
M25825	tctex-1	-0.959	-1.9	D50663
C77864	Similar to Chinese hamster for $\beta$ tubulin	-0.991	n/a	BC012835
aa111610	Similar to tuftelin-interacting protein 10	0.950	n/a	BC013051
AA138226	Similar to rat clathrin light chain (LCB3)	0.956	1.1	BC006457
m75720	$\alpha$ -1 protease inhibitor 3	0.955	n/a	XM_028358
C76274	Similar to <i>Mus musculus</i> ligatin (Lgtn)	-0.955	n/a	XM_051973
aa204573	Similar to human spindle pole body protein	-0.972	-1.5	XM_027551
<i>Transcription factors</i>				
W87135	Single stranded DNA binding protein p9	0.973	2.2	X79805
af003866	Pale ear (ep wild type allele)	-0.982	-2.1	XM_050813
AB001990	Dcra	-0.985	-1.4	NM_006052
m11943	Int-1 proto-oncogene	0.956	4	XM_006776
u67840	Dlx5	-0.988	n/a	XM_004848
Z32675	Hairless protein	-0.956	-1.9	NM_018411
AJ002366	Transcription factor TFIIH, 62 kD subunit	-0.968	n/a	BC000365
U41285	Dishevelled-3 (Dvl-3)	-0.951	-1.5	XM_029104
L38607	BF-2 transcription factor	0.944	n/a	XM_003984
aa710439	BACH1	-0.986	n/a	XM_009718
W83286	Similar to <i>H. sapiens</i> RNA polymerase II	0.967	1.4	NM_006232
D14336	RNA polymerase I associated factor	-0.972	-1.5	AK024032
<i>Others</i>				
aa711217	Similar to NADH-ubiquinone oxidoreductase	0.960	1.4	AF035839
aa521794	Similar to cytochrome <i>c</i> oxidase	-0.961	-1.6	XM_041174
M36660	NAD(P) H menadione oxidoreductase	-0.958	n/a	J03934
af015284	Selenoprotein W (mSelW)	-0.992	n/a	U67171
M99054	Acid phosphatase type 5 gene	-0.960	-1.5	X67123
aa543785	Thymic dendritic cell-derived factor 1	0.985	1.5	XM_038905
J02809	Neural specific calmodulin-binding protein	-0.954	n/a	XM_045289
aa061099	Ribonuclease HI	-0.980	-3.3	NM_006397
C78741	Poly(A) binding protein II (mPABII)	-0.951	-1.4	AF026029

<u>Mouse Gene Accession No.</u>	<u>Description</u>	<u>r value</u>	<u>Fold</u>	<u>Human Homologue Accession No.</u>
AA230943	Similar to mouse Sm-B	-0.952	-2.1	XM_044910
aa544831	Similar to renin-binding protein	-0.973	-2.5	XM_013053
U12564	129 defensin-like gene 4C-2	0.971	n/a	N/A
c79315	Similar to <i>M. musculus</i> tex 292	0.971	1.6	XM_039300
L06234	Dihydropyridine-sensitive calcium channel	-0.969	n/a	XM_001910
U62021	Neuronal pentraxin 1 (NPTX1)	-0.951	-2.1	NM_002522
aa560507	Similar to antiquitin	-0.984	-1.6	BC002515
z72000	BTG3	0.959	2.1	XM_012976
af003346	Ubiquitin-conjugating enzyme UbcM2	0.982	1.7	AF085362
AA072822	Testosterone 15- $\alpha$ -hydroxylase	-0.957	n/a	XM_030948
aa547057	Similar to HT Protein	-0.979	-1.4	BC002894
<i>Metabolism</i>				
AA146156	Keratinocyte lipid binding protein (Klbp)	0.986	8.6	XM_015760
AA120674	Similar to <i>Homo sapiens</i> acylephosphatase 2	0.964	2.3	NM_001108 BC012290
U21489	Long-chain acyl-CoA dehydrogenase	-0.963	-1.6	XM_002386
aa592828	Aldo-keto reductase AKR1C1	0.977	2.2	N/A
ET63206	Fructose-1,6-biphosphatase	0.960	n/a	N/A

## CLAIM OR CLAIMS

## I/WE CLAIM:

1. A method for the diagnosis of diabetes in an individual comprising the step of determining the expression pattern in the adipose tissue of the individual of any of the genes listed in Tables 1, 2 and 3 to determine if the individual has diabetic disease.

2. A method as claimed in claim 1 wherein the gene is SREBP.

3. A method for the diagnosis of diabetes in an individual comprising the step of determining the expression pattern in the adipose tissue of the individual of a subset of the genes listed in Tables 1, 2 and 3, that subset being determinative of diabetic disease.

4. A method for the diagnosis of diabetes in an individual comprising the step of determining the expression pattern in the adipose tissue of the individual of at least four genes, the four genes selected from at least four of the gene groupings listed on Table 1 or Table 2.

5. A method for the diagnosis of diabetes in an individual comprising the steps of taking a sample of adipose tissue from the individual; and  
determining the expression pattern of a gene in the adipose tissue of the individual to determine if the individual has diabetic disease or a genetic predisposition to diabetic disease.

6. A method for the diagnosis of diabetes in an individual comprising the step of determining the expression pattern in the adipose tissue of the individual of at least four of the genes listed in Tables 1 and 2, those genes being determinative as to whether the individual has diabetic disease.

7. A method as claimed in claim 4 wherein the genes are selected from at least four of the gene groupings in the group consisting of hormone and signal transduction genes, mitochondrial genes, lipid metabolism genes, transcription factor genes, secreted protein genes, cytoskeletal genes, lysosomal genes, immune/complement genes, cell proliferation genes, adipose-specific genes, and membrane protein genes.

8. A method for the diagnosis of susceptibility of an individual to diabetes comprising assaying the expression level of the gene SREBP in the adipose tissue of the individual.

9. A method for the diagnosis of the development of insulin resistance comprising the steps of

determining the expression patterns in adipose tissue of the individual of the genes listed in Table 3 to determine if the individual has developed insulin resistance.

10. A method for the diagnosis of insulin resistance in an individual comprising the step of determining the expression pattern in the adipose tissue of the individual of at least four of the genes listed in Table 3, those genes being determinative as to whether the individual has developed insulin resistance.

11. A method for the diagnosis or prognosis of obesity, incipient obesity, or the transition from obese to diabetic, in an individual, comprising the step of

determining the expression pattern in the adipose tissue of the individual of any of the genes listed in Tables 1, 2 and 3 to determine if the individual has gene expression consistent with said diagnosis or prognosis.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number  
**WO 02/022886 A3**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68, A01K 67/027

(21) International Application Number: PCT/US01/29096

(22) International Filing Date:  
18 September 2001 (18.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/233,339 18 September 2000 (18.09.2000) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: ATTIE, Alan, D.; 1906 Vilas Avenue, Madison, WI 53711 (US). NADLER, Samuel, T.; 909 South Brooks Apartment 7, Madison, WI 53715 (US).

(74) Agent: SEAY, Nicholas, J.; Quarles & Brady LLP, P.O. Box 3113, Madison, WI 53701-2113 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
20 November 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: EXPRESSION OF GENES IN DIABETES MELLITUS AND INSULIN RESISTANCE

(57) Abstract: A gene expression pattern analysis has identified genes the expression patterns of which are different in adipose cells of individuals who have Type 2 Diabetes Mellitus from the cells of individuals who do not have the disease. This information provides a mechanism for the genetic diagnosis of the disease.



WO 02/022886 A3

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/29096

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARVALHO EUGENIA ET AL: "Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM." FASEB JOURNAL, vol. 13, no. 15, December 1999 (1999-12), pages 2173-2178, XP002231943 ISSN: 0892-6638 abstract page 2174, column 2, paragraph 1; figure 2; tables 1,2 page 2175, column 1, paragraph 1 -column 2, paragraph 1 page 2176, column 1, paragraph 2 -page 2177, column 1, paragraph 2 page 2177, column 2, paragraph 3 --- -/--	5

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 February 2003

Date of mailing of the international search report

01.07.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Tilkorn, A-C



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/29096

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SOUKAS ALEXANDER ET AL: "Leptin-specific patterns of gene expression in white adipose tissue." GENES & DEVELOPMENT, vol. 14, no. 8, 15 April 2000 (2000-04-15), pages 963-980, XP002231944 ISSN: 0890-9369	11
Y	abstract page 964, column 1, paragraph 2 - paragraph 4 page 964, column 2, paragraph 2 -page 966, column 2, paragraph 1 page 969, column 1, paragraph 5 -page 971, column 1, paragraph 1 page 974, column 1, paragraph 1 -column 2, paragraph 3 page 975, column 1, paragraph 4 -page 976, column 2, paragraph 2 page 977, column 2, paragraph 3 -page 978, column 1, paragraph 3; figures 1,4,6,7; tables 1,4	1-8
Y	----- KAHN BARBARA B ET AL: "Obesity and insulin resistance." JOURNAL OF CLINICAL INVESTIGATION, vol. 106, no. 4, August 2000 (2000-08), pages 473-481, XP002231945 ISSN: 0021-9738 page 473, column 2, paragraph 1 -page 474, column 1, paragraph 4; figure 1 column 1	1-8
Y	----- VIDAL-PUIG ANTONIO ET AL: "Obesity and diabetes: An avalanche of new information: The molecular mechanisms and genetics of diabetes mellitus and molecular control of adipogenesis and obesity, Keystone Symposium: Taos Civic Center, Taos, NM, USA, 16-22 February 2000." MOLECULAR MEDICINE TODAY, vol. 6, no. 6, June 2000 (2000-06), pages 221-223, XP002231946 ISSN: 1357-4310 page 221, column 1, paragraph 2 -column 2, paragraph 1 ----- -/-	1-8

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/29096

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SHIMOMURA I ET AL: "INSULIN RESISTANCE AND DIABETES MELLITUS IN TRANSGENIC MICE EXPRESSING NUCLEAR SREBP-1C IN ADIPOSE TISSUE: MODEL FOR CONGENITAL GENERALIZED LIPODYSTROPHY" GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 12, 1998, pages 3182-3194, XP002926780 ISSN: 0890-9369 abstract page 3182, column 1, paragraph 1 page 3183, column 2, paragraph 3 -page 3184, column 1, paragraph 1 page 3186, column 2, paragraph 3 -page 3188, column 1, paragraph 3; figures 5,8	1-8
P,X	DUCLUZEAU PIERRE-HENRI ET AL: "Regulation by insulin of gene expression in human skeletal muscle and adipose tissue: Evidence for specific defects in type 2 diabetes." DIABETES, vol. 50, no. 5, May 2001 (2001-05), pages 1134-1142, XP002231947 ISSN: 0012-1797 abstract page 1138, column 1, paragraph 3 -column 2, paragraph 1 page 1140, column 2, paragraph 6 -page 1141, column 2, paragraph 3; figure 4	1-8,11
P,X	NADLER SAMUEL T ET AL: "The expression of adipogenic genes is decreased in obesity and diabetes mellitus" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11371-11376, XP002203186 ISSN: 0027-8424 abstract page 11374, column 1, paragraph 2 page 11375, column 1, paragraph 8; figures 1,2; table 1	1-8,11

-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/29096

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>NADLER SAMUEL T ET AL: "Please pass the chips: Genomic insights into obesity and diabetes."</p> <p>JOURNAL OF NUTRITION, vol. 131, no. 8, August 2001 (2001-08), pages 2078-2081, XP002231948 ISSN: 0022-3166 abstract page 2079, column 1, paragraph 4 -column 2, paragraph 2 page 2079, column 2, paragraph 4; figure 1</p>	1-8,11

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/29096

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 5  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claim 5 relates to a method that involves an in vivo step i.e. "taking a sample of adipose tissue from the individual" and thus falls under Rule 39.1(iv) PCT. The search of said claim has been based on the alleged effects of the method.
2. ☒ Claims Nos.: 3,4,6,7,10 (partially)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
2, 8 (completely), 1, 3-7, 11 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 2,8 (completely), 1,3-7,11 (partially)

method for the diagnosis of diabetes, the susceptibility to diabetes or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of SREBP in the adipose tissue.

## 2. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of Fyn the adipose tissue.

## 3. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of Flk-2 in the adipose tissue.

## 4. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of BF-2 in the adipose tissue.

## 5. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of int-1 in the adipose tissue.

## 6. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of Dvl-3 in the adipose

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

tissue.

7. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of Dlx5 in the adipose tissue.

8. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of the transcription factor Pale Ear (ep) in the adipose tissue.

9. Claims: 1,3,5,9-11(partially)

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of tctex-1 in the adipose tissue.

10. Claims: 1,3-7,11(partially)

Inventions 10-127:

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of each of the genes listed in Tables 1 and 2 in the adipose tissue.

11. Claims: 1,3,5,9-11 (partially)

Inventions 128-190:

method for the diagnosis of diabetes, the susceptibility to diabetes, of insulin resistance or its development or a method for the diagnosis or prognosis of obesity, incipient obesity or the transition from obese to diabetic comprising determining the expression pattern of each of the genes

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

listed in Table 3 in the adipose tissue.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01 29096

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 3,4,6,7,10 (partially)

The following remarks as to the incomplete search apply only to the invention searched i.e. invention 1 (see invitation to pay additional fees). Similar remarks would apply to the other inventions (inventions 2-190) should additional search fees be paid.

Present claims 3,4,6,7 and 10 relate to an extremely large number of possible methods, because they require the analysis of gene expression pattern of an undefined combination of genes (e.g. a subset, at least four) from Tables 1-3 which contain a list of 190 genes altogether. However, the application lacks support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for all of the possible combinations claimed. Therefore, a meaningful search over the whole of the claimed scope is impossible. Consequently, a search has been carried out only for the differential expression of an individual gene.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.